201 related articles for article (PubMed ID: 33709196)
1. Impact of Formulation Parameters on In Vitro Release from Long-Acting Injectable Suspensions.
Bao Q; Zou Y; Wang Y; Choi S; Burgess DJ
AAPS J; 2021 Mar; 23(2):42. PubMed ID: 33709196
[TBL] [Abstract][Full Text] [Related]
2. Development of in vitro-in vivo correlations for long-acting injectable suspensions.
Bao Q; Wang X; Wan B; Zou Y; Wang Y; Burgess DJ
Int J Pharm; 2023 Mar; 634():122642. PubMed ID: 36709013
[TBL] [Abstract][Full Text] [Related]
3. In vitro release testing method development for long-acting injectable suspensions.
Bao Q; Wang X; Zou Y; Wang Y; Burgess DJ
Int J Pharm; 2022 Jun; 622():121840. PubMed ID: 35595043
[TBL] [Abstract][Full Text] [Related]
4. Probing in Vitro Release Kinetics of Long-Acting Injectable Nanosuspensions via Flow-NMR Spectroscopy.
Rudd ND; Helmy R; Dormer PG; Williamson RT; Wuelfing WP; Walsh PL; Reibarkh M; Forrest WP
Mol Pharm; 2020 Feb; 17(2):530-540. PubMed ID: 31895571
[TBL] [Abstract][Full Text] [Related]
5. Interpreting
Rudd ND; Reibarkh M; Fang R; Mittal S; Walsh PL; Brunskill APJ; Forrest WP
Mol Pharm; 2020 May; 17(5):1734-1747. PubMed ID: 32267708
[TBL] [Abstract][Full Text] [Related]
6. Development of long-acting injectable suspensions by continuous antisolvent crystallization: An integrated bottom-up process.
Nandi S; Padrela L; Tajber L; Collas A
Int J Pharm; 2023 Dec; 648():123550. PubMed ID: 37890647
[TBL] [Abstract][Full Text] [Related]
7. Linking
Nguyen V; Bevernage J; Darville N; Tistaert C; Van Bocxlaer J; Rossenu S; Vermeulen A
Mol Pharm; 2021 Mar; 18(3):952-965. PubMed ID: 33400546
[TBL] [Abstract][Full Text] [Related]
8. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
9. Prilling of API/fatty acid suspensions: Processability and characterisation.
De Coninck E; Vanhoorne V; Elmahdy A; Boone M; Van Assche G; Markl D; De Geest BG; De Beer T; Vervaet C
Int J Pharm; 2019 Dec; 572():118756. PubMed ID: 31648017
[TBL] [Abstract][Full Text] [Related]
10. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
[TBL] [Abstract][Full Text] [Related]
11. Application of solid lipid nanoparticles as a long-term drug delivery platform for intramuscular and subcutaneous administration: In vitro and in vivo evaluation.
Elbrink K; Van Hees S; Chamanza R; Roelant D; Loomans T; Holm R; Kiekens F
Eur J Pharm Biopharm; 2021 Jun; 163():158-170. PubMed ID: 33848628
[TBL] [Abstract][Full Text] [Related]
12. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
13. A sensitive in vitro performance assay reveals the in vivo drug release mechanisms of long-acting medroxyprogesterone acetate microparticles.
Gao GF; Thurn M; Wendt B; Parnham MJ; Wacker MG
Int J Pharm; 2020 Aug; 586():119540. PubMed ID: 32590096
[TBL] [Abstract][Full Text] [Related]
14. Accelerated and Biopredictive In Vitro Release Testing Strategy for Single Agent and Combination Long-Acting Injectables.
Jain KMH; Ho T; Hoe S; Wan B; Muthal A; Subramanian R; Foti C
J Pharm Sci; 2024 Jul; 113(7):1885-1897. PubMed ID: 38369022
[TBL] [Abstract][Full Text] [Related]
15. In vitro behavior of dronedarone hydrochloride loaded pellets using vacuum impregnation technique.
Gretić M; Štanfel M; Barbarić J; Rimac N; Matijašić G
Eur J Pharm Biopharm; 2021 May; 162():70-81. PubMed ID: 33727144
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig.
Tao Y; Yang F; Meng K; Chen D; Yang Y; Zhou K; Luo W; Qu W; Pan Y; Yuan Z; Xie S
Drug Deliv; 2019 Dec; 26(1):273-280. PubMed ID: 30880494
[TBL] [Abstract][Full Text] [Related]
17. Tailoring the use of excipients in bottom-up production of naproxen crystal suspensions via membrane technology.
Anjum F; Wessner M; De Witte B; Al-Rifai N; Collas A; Sadowski G
Int J Pharm; 2024 Mar; 652():123846. PubMed ID: 38272195
[TBL] [Abstract][Full Text] [Related]
18. The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets.
Van Renterghem J; Dhondt H; Verstraete G; De Bruyne M; Vervaet C; De Beer T
Int J Pharm; 2018 Apr; 541(1-2):108-116. PubMed ID: 29409747
[TBL] [Abstract][Full Text] [Related]
19. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection.
Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS
Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104
[TBL] [Abstract][Full Text] [Related]
20. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
Veith H; Wiechert F; Luebbert C; Sadowski G
Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
